Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide:A Phase III, Open-Label, Randomized Trial.
Palumbo A et al
J Clin Oncol. 2011 Jan 31. [Epub ahead of print]
FRAGMINE (daltéparine)
Synthèse d’avis de la Commission de transparence
Janvier 2011
FRAGMINE (daltéparine)
Avis de la Commission de Transparence
30 juin 2010
Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism.
L Knowlson, S Bacchu, S Paneesha, A McManus, K Randall, P Rose.
J Clin Pathol 2010 63: 818-822.
Commentaire (17/12/2010)
TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Nashat Gabrail, MD, Eric Sandler, MD, Veena Charu, MD, Nick Anas, MD, Eduardo Lim, MD, Martha Blaney, PharmD, Mark Ashby, PhD, Barbara S. Gillespie, MD, and Susan M. Begelman, MD
J Vasc Interv Radiol 2010; 21:1852–1858
Commentaire (17/12/2010)
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN.
J Thromb Haemost. 2010 Sep;8(9):1959-65.
Commentaire (17/12/2010)
Prediction of venous thromboembolism in cancer patients.
Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I.
Blood. 2010 Dec 9;116(24):5377-82. Epub 2010 Sep 9.
Commentaire(17/12/2010)
Abstract